Psyence Biomed Announces Export Of Nature-Derived Psilocybin To Australia And Provides Update On Upcoming Phase IIb Trial As A Potential Treatment For Adjustment Disorder Following An Advanced Cancer Diagnosis In The Palliative Care Context
Portfolio Pulse from Benzinga Newsdesk
Psyence Biomed Ltd. (NASDAQ:PBM) announced the export of nature-derived psilocybin to Australia and provided an update on its upcoming Phase IIb clinical trial for treating Adjustment Disorder in palliative care. The trial will start shortly after the drug product is received by trial sites.
July 24, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Psyence Biomed Ltd. (NASDAQ:PBM) has successfully exported nature-derived psilocybin to Australia and is set to begin a Phase IIb clinical trial for treating Adjustment Disorder in palliative care. This development could positively impact the company's stock in the short term.
The successful export of the drug and the imminent start of the Phase IIb trial are significant milestones for Psyence Biomed. These developments could lead to positive investor sentiment and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100